Loading company details...
Beta
Latest Form 4 (Sep 30, 2026): Daniel Karlin (Chief Medical Officer): Sale of 10,853 shares, $396.9K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Daniel Karlin, Chief Medical Officer | Sale | 10,853 | $396.9K |
| Sep 30, 2026 | Robert Barrow, Chief Executive Officer | Sale | 31,550 | $1.15M |
| Sep 30, 2026 | Matthew T. Wiley, Chief Commercial Officer | Sale | 3,097 | $113.3K |
| Sep 30, 2026 | Mark Sullivan, Chief Legal Officer | Sale | 14,051 | $513.8K |
| Sep 30, 2026 | Brandi Roberts, Chief Financial Officer | Sale | 3,377 | $123.5K |
| Sep 19, 2026 | Carol A. Vallone | Exercise/Conversion | 1,086 | $38.6K |
| Sep 19, 2026 | Andreas Krebs | Exercise/Conversion | 1,629 | $57.9K |
| Sep 14, 2026 | Daniel Karlin, Chief Medical Officer | Grant/Award | 200,000 | n/a |
| Sep 14, 2026 | Matthew T. Wiley, Chief Commercial Officer | Grant/Award | 125,000 | n/a |
| Sep 14, 2026 | Mark Sullivan, Chief Legal Officer | Grant/Award | 125,000 | n/a |